Search clinical trials for: Arixtra (fondaparinux sodium)

Total 10515 results

Paul Di Cesare,MD

Completed

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

Total Knee Replacement

United States
Lehigh Valley Hospital
GlaxoSmithKline

Terminated

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients (BRiEF)

Venous Thrombosis

United States
NYU Langone Health
GlaxoSmithKline

Withdrawn

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Ovarian Carcinoma

United States
Northwell Health
GlaxoSmithKline

Terminated

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

Cancer | Thromboembolism

United States
Melbourne Health

Terminated

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

Renal Failure

Australia
Mary Knudson, M.D.
GlaxoSmithKline

Completed

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Venous Thromboembolism

United States
University of Alabama at Birmingham
GlaxoSmithKline

Terminated

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

Venous Thrombosis

United States
Masonic Cancer Center, University of Minnesota

Completed

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Thromboembolism | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer

United States
Università degli Studi dell'Insubria

Terminated

Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency

Renal Insufficiency | Medical Patients

Italy
Duke University
GlaxoSmithKline

Withdrawn

Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Kidney Diseases

United States
University of Louisville
James Graham Brown Cancer Center

Terminated

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia

United States
The New England Baptist Hospital

Unknown

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery (DVT)

Pulmonary Embolism

United States
Wayne State University
GlaxoSmithKline

Unknown

Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

ICU Patients 18 Years or Older.

United States
Methodist Healthcare
University of Tennessee

Withdrawn

Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia
Children's Hospital Los Angeles

Completed

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

Thrombosis | Heparin-induced Thrombocytopenia

United States
The Cleveland Clinic
GlaxoSmithKline

Withdrawn

Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux

Pulmonary Embolism

United States
G. d'Annunzio University

Terminated

Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia (FAITH)

Thrombocytopenia | Medical Patient

Italy
Weill Medical College of Cornell University

Terminated

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (IMPACT)

COVID-19

United States
Wayne State University
GlaxoSmithKline

Completed

Fondaparinux in Critically Ill Patients With Renal Failure

Venous Thromboembolism

United States
GWT-TUD GmbH
Bayer

Completed

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Superficial Vein Thrombosis

Germany
Eastern Virginia Medical School
GlaxoSmithKline

Terminated

Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

Venous Thromboembolism
University of Alabama at Birmingham

Completed

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Venous Thromboembolism

United States
Red Cross Hospital Beverwijk

Unknown

Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures (PROTECT)

Deep Vein Thrombosis | Pulmonary Embolism

Netherlands
GlaxoSmithKline

Completed

ARIXTRA Local Study For Registration In China.

Thromboembolism | Knee Replacement | Hip Replacement

China
GlaxoSmithKline

Completed

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

Cardiovascular Disease
University of Pittsburgh
GlaxoSmithKline

Completed

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

Venous Thrombosis | Pulmonary Embolism

United States
GlaxoSmithKline
Sanofi

Completed

A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

Thromboembolism
GlaxoSmithKline

Completed

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

Cardiovascular Disease
GlaxoSmithKline

Completed

Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

Venous Thromboembolism

Japan
GlaxoSmithKline

Completed

Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Ataxia
GlaxoSmithKline

Completed

Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

Ataxia
Duke University
GlaxoSmithKline

Completed

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" (FONDA PK)

Renal Insufficiency

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery (FONDACAST)

Thrombosis, Venous

Spain, Germany, Russian Federation, France, Italy, Netherlands
GlaxoSmithKline

Completed

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA/OASIS 8)

Acute Coronary Syndrome

Canada, France, Bulgaria, Germany, Poland, United Kingdom, Spain, Russian Federation, Korea, Republic of, Netherlands, India, United States, Brazil, Hungary, Italy, Argentina, Czech Republic, Greece
Schering-Plough

Withdrawn

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Myocardial Infarction | Coronary Disease

United States, France, Canada
National Medical Research Center for Therapy and...

Completed

Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Endovenous Laser Ablation | Superficial Vein Thrombosis

Russian Federation
GlaxoSmithKline
Sanofi

Completed

OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Thromboembolism
Shanghai Zhongshan Hospital

Completed

The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery

Lung Neoplasms | Esophageal Neoplasms | Venous Thromboembolism

China
GlaxoSmithKline

Completed

Hemorrhage Risk Prescribed Arixtra

Thrombosis, Venous
GlaxoSmithKline

Completed

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Thrombosis, Venous

Japan
University of Veterinary and Animal Sciences, Lahore...

Not yet recruiting

Evaluation of Licorice Root on Metabolic Syndrome in Polycystic Ovary Syndrome Females

Polycystic Ovary Syndrome | Metabolic Syndrome
University of Delaware

Completed

Adverse Neurogenic Actions of Dietary Salt

Blood Pressure

United States
Children's Hospital of Philadelphia

Withdrawn

Gastrointestinal Implications of Voriconazole Exposure (GIVE)

Infection

United States
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute

Completed

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS)

Cancer | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Blood Clot

United States
GlaxoSmithKline

Completed

Fondaparinux EU-RMP (Adherence)

Acute Coronary Syndrome
GlaxoSmithKline

Completed

Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism (FondaPPP)

Thromboembolism | Venous Thromboembolism

Germany
GlaxoSmithKline

Completed

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Embolism, Pulmonary

Japan
Indiana University School of Medicine
American Society for Bariatric Surgery

Withdrawn

Study to Determine Effective Dosing of Fondaparinux in Obese Persons

Morbid Obesity

United States
Centre Hospitalier Universitaire de Saint Etienne
GlaxoSmithKline

Completed

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux. (PROPICE)

Major Orthopaedic Surgery and Renal Impairment

France
GlaxoSmithKline

Completed

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Thrombosis, Venous

Netherlands, Spain, Germany, Italy, Poland, Russian Federation, France, Israel, Estonia, Hungary, Slovakia, Latvia, Greece, Ukraine, Czech Republic, Switzerland, Bulgaria

3

Subscribe